title: Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of intraoperative subconjunctival bevacizumab as an adjunctive treatment after surgical excision of primary pterygium.
  
  
  METHODS
  This was a randomized prospective clinical study. Group 1 (21 eyes) underwent pterygium excision with conjunctivo-limbal autograft. Group 2 (20 eyes) received subconjunctival 1.25 mg/0.05 mL of bevacizumab at the end of the surgery.
  
  
  RESULTS
  There were no statistically significant differences regarding age, sex, laterality, or dimensions of the pterygia or grafts between the two groups (P > .05, 95% confidence interval). After 8 months of follow-up, two eyes in group 1 and four eyes in group 2 had recurrent pterygia. One patient in group 2 had lost graft. The difference in recurrence rate between the two groups did not reach statistical significance (P = 0.4, 95% confidence interval).
  
  
  CONCLUSIONS
  Intraoperative subconjunctival bevacizumab following primary pterygium surgical excision is not helpful and possibly harmful. Larger studies are needed.
authors.affiliation: Ophthalmology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. mahashahin@msn.com
authors.forename: Maha M
authors.initials: MM
authors.lastname: Shahin
authors.forename: Amal M
authors.initials: AM
authors.lastname: Elbendary
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: Elwan
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant; D003228:Conjunctiva / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000601:surgery; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab